Announcements Trials
Browse Landscape

Phase

Phase 2 7Phase 4 1Phase 3 1

Status

Completed 1

Sponsor Class

INDUSTRY 1

Study Type

Interventional 1

Sponsor

Cancer Type

Genitourinary 5Gastrointestinal 3Sarcoma 2Thoracic 1Other solid neoplasm 1NET 1Head & Neck 1Gynecologic 1Endocrine 1Breast 1

Conditions

Pancreatic Neoplasms 1Neuroendocrine Tumors 1Neoplasms 1Carcinoma 1Adenoma 1

Interventions

Octreotide 4Everolimus 4lanreotide 3pasireotide 2Carboplatin 2surufatinib 1lutetium Lu 177 dotatate 1gadoteridol 1gadoterate meglumine 1gadolinium ethoxybenzyl DTPA 1gadodiamide 1gadobutrol 1gadobenic acid 1arginyllysine 1Surveys and Questionnaires 1Sunitinib 1Somatostatin 1Positron Emission Tomography Computed Tomography 1Paclitaxel 1Neuropsychological Tests 1Magnetic Resonance Spectroscopy 1Diazoxide 1Cisplatin 1Cabergoline 164Cu-DOTATATE 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Phase 4 × Sunitinib × NET × Clear all
NCT01525550 2019-07-30

A Study Of The Efficacy And Safety Of Sunitinib In Patients With Advanced Well-Differentiated Pancreatic Neuroendocrine Tumors

Pfizer

Phase 4 Completed
106 enrolled 26 charts
EndocrineGastrointestinalNET

Adenoma, Carcinoma, Neoplasms, Pancreatic Neoplasms, Neuroendocrine Tumors

Data powered by HemOnc (CC BY 4.0) Colophon âš¡